Dianthus Therapeutics, INC. /De/ (DNTH) — SEC Filings

Overview

Dianthus Therapeutics, INC. /De/ (DNTH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Dianthus Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 8.01, indicating an 'Other Event' and including an exhibit EX-99.1. While the specific details of the event are not provided in the summary, the filing suggests a significant, non-routine occurrence that the company deemed import

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 33 neutral, 4 mixed. The dominant filing sentiment for Dianthus Therapeutics, INC. /De/ is neutral.

Filing Type Overview

Dianthus Therapeutics, INC. /De/ (DNTH) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13D/A, 6 SC 13G, 4 SC 13G/A, 2 S-1/A, 1 SC 13D with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• Dianthus Therapeutics Files 8-K for 'Other Event' on March 26, 2026 — 8-K · Mar 26, 2026
  Dianthus Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 8.01, indicating an 'Other Event' and including an exhibit EX-99.1. While the specific de
• Dianthus's Net Loss Widens 73% Amid Soaring R&D, Cash Reserves Up — 10-Q · Nov 5, 2025 Risk: high
  Dianthus Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $97.905 million, up from $56.529
• Dianthus Therapeutics Files 8-K — 8-K · Nov 3, 2025 Risk: low
  On November 3, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• Dianthus Therapeutics Files 8-K — 8-K · Oct 16, 2025 Risk: low
  Dianthus Therapeutics, Inc. filed an 8-K on October 16, 2025, reporting on the entry into a material definitive agreement, results of operations and financial c
• Dianthus Therapeutics Enters Material Definitive Agreement — 8-K · Sep 11, 2025 Risk: medium
  Dianthus Therapeutics, Inc. announced on September 9, 2025, that it entered into a material definitive agreement. The company, formerly known as Magenta Therape
• Dianthus Therapeutics Files 8-K Report — 8-K · Sep 8, 2025 Risk: low
  On September 8, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Finan
• Dianthus's Net Loss Widens to $45.2M Amid Rising R&D Costs — 10-Q · Aug 7, 2025 Risk: high
  Dianthus Therapeutics, Inc. reported no revenue for the six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the
• Dianthus Therapeutics Files 8-K on Officer/Director Changes — 8-K · May 22, 2025 Risk: medium
  Dianthus Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointmen
• Dianthus Therapeutics Q1 2025 Update — 10-Q · May 12, 2025 Risk: low
  Dianthus Therapeutics, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's former name was Magenta Therapeutics, In
• Dianthus Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 10, 2025 Risk: low
  Dianthus Therapeutics, Inc. filed a DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals li
• Dianthus Therapeutics Files 2024 10-K — 10-K · Mar 11, 2025 Risk: medium
  Dianthus Therapeutics, Inc. filed its 2024 10-K on March 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Magenta Therapeu
• Dianthus Therapeutics Appoints New CMO, Director — 8-K · Mar 5, 2025 Risk: medium
  Dianthus Therapeutics, Inc. announced on March 4, 2025, a change in its board of directors. Specifically, Dr. Jonathan Jonathan, a director, resigned from his p
• Dianthus Therapeutics Files 8-K — 8-K · Dec 12, 2024 Risk: low
  Dianthus Therapeutics, Inc. filed an 8-K on December 12, 2024, to report other events and financial statements. The company, formerly known as Magenta Therapeut
• Avidity Partners Amends Stake in Dianthus Therapeutics — SC 13D/A · Dec 3, 2024 Risk: medium
  Avidity Partners Management LP, through its filing on December 3, 2024, has amended its Schedule 13D regarding Dianthus Therapeutics, Inc. The filing indicates
• SC 13G Filing — SC 13G · Nov 22, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Dianthus Therapeutics Q3 2024 Update — 10-Q · Nov 7, 2024 Risk: medium
  Dianthus Therapeutics, Inc. reported its third quarter 2024 results, ending September 30, 2024. The company's financial statements show changes in various equit
• SC 13G Filing — SC 13G · Oct 24, 2024
• SC 13G Filing — SC 13G · Oct 11, 2024
• Dianthus Therapeutics Appoints New Director — 8-K · Sep 16, 2024 Risk: low
  Dianthus Therapeutics, Inc. announced on September 16, 2024, a change in its board of directors. Specifically, Dr. Jonathan Leff has been appointed as a Class I
• Viridian LLC Amends Stake in Dianthus Therapeutics — SC 13D/A · Sep 12, 2024 Risk: medium
  Viridian, LLC, a significant shareholder, filed an amendment to its Schedule 13D on September 12, 2024, regarding its holdings in Dianthus Therapeutics, Inc. Th
• Dianthus Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Dianthus Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
• Dianthus Therapeutics Files 8-K for Disclosure — 8-K · Jun 6, 2024 Risk: low
  Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) filed an 8-K on June 6, 2024, to report a Regulation FD Disclosure and Financial Statements an
• Dianthus Therapeutics Announces Corporate Changes — 8-K · May 28, 2024 Risk: medium
  Dianthus Therapeutics, Inc. announced on May 23, 2024, a series of significant corporate actions. These include the election of new directors, the appointment o
• Dianthus Therapeutics Files 10-Q for Q1 2024 — 10-Q · May 9, 2024 Risk: medium
  Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Dianthus Therapeutics, Inc. filed its 10-Q for the period e
• Dianthus Therapeutics Announces 2024 Annual Meeting of Stockholders on May 23 — DEF 14A · Apr 11, 2024 Risk: low
  Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. The 2024 Annual Meeting of Stockholders for Dianthus T
• Fairmount Funds Adjusts Stake in Dianthus Therapeutics — SC 13D/A · Apr 1, 2024 Risk: medium
  Fairmount Funds Management LLC, through its affiliated entities and individuals Peter Harwin and Tomas Kiselak, has amended its Schedule 13D filing concerning D
• Dianthus Therapeutics Files S-1/A Amendment — S-1/A · Mar 21, 2024 Risk: medium
  Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Amended IPO Registration (S-1/A) with the SEC on March 21, 2024. Dianthus Therapeutics, Inc. filed an S-1/A amen
• Dianthus Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 21, 2024 Risk: medium
  Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Annual Report (10-K) with the SEC on March 21, 2024. Dianthus Therapeutics, Inc. filed its 2023 Form 10-K on Mar
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• GV 2016, L.P. Amends Dianthus Therapeutics Ownership — SC 13G/A · Feb 9, 2024 Risk: low
  GV 2016, L.P., a venture capital firm associated with Alphabet, filed an amended SC 13G/A on February 9, 2024, for Dianthus Therapeutics, Inc. (formerly Magenta
• Dianthus Therapeutics Files S-1/A Amendment — S-1/A · Feb 7, 2024 Risk:
  Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Amended IPO Registration (S-1/A) with the SEC on February 7, 2024. Dianthus Therapeutics, Inc. filed an S-1/A am
• BCLS Fund III Investments Takes 5.0% Stake in Dianthus Therapeutics — SC 13G · Feb 2, 2024
  BCLS Fund III Investments, LP, a Boston-based investment fund, has reported a significant stake in Dianthus Therapeutics, Inc. /DE/, a pharmaceutical company. A
• RA Capital Discloses Significant Stake in Dianthus Therapeutics — SC 13G · Feb 2, 2024
  RA Capital Management, L.P., a Boston-based investment firm, filed an SC 13G on February 2, 2024, disclosing its ownership in Dianthus Therapeutics, Inc. /DE/.
• Avidity Partners Takes 5.1% Stake in Dianthus Therapeutics — SC 13D · Jan 31, 2024
  Avidity Partners Management LP, a Dallas-based investment firm, has filed an SC 13D, indicating they now beneficially own 5.1% of Dianthus Therapeutics, Inc.'s
• Fairmount Funds Management Amends 13D for Dianthus Therapeutics — SC 13D/A · Jan 24, 2024
  Fairmount Funds Management LLC, along with its affiliated funds (Fairmount Healthcare Fund II LP, Fairmount Healthcare Fund LP, and Fairmount SPV III, LLC) and
• Dianthus Therapeutics Reports Material Agreement, Unregistered Equity Sales — 8-K · Jan 22, 2024
  Dianthus Therapeutics, Inc. filed an 8-K on January 22, 2024, to report an entry into a material definitive agreement and unregistered sales of equity securitie
• Dianthus Therapeutics Relocates HQ to NYC, Updates Phone — 8-K · Jan 8, 2024
  Dianthus Therapeutics, Inc. filed an 8-K on January 8, 2024, to update its principal executive offices from Cambridge, MA to 7 Times Square, 43rd Floor, New Yor

Risk Profile

Risk Assessment: Of DNTH's 25 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Dianthus Therapeutics, INC. /De/'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: $1,752,000
• Net Income: -$97,905,000
• EPS: N/A
• Debt-to-Equity: 0.06
• Cash Position: $402,613,000
• Operating Margin: N/A
• Total Assets: $577,445,000
• Total Debt: $30,991,000

Key Executives

• Ryan Savitz
• Marino Garcia
• Dr Jason Gardner
• Stephen Mahoney
• Jonathan Jonathan
• Sarah Chen
• Dee Raibourn, Esq.
• Dr. Jonathan Leff
• Ryan A. Murr
• Leon O. Moulder, Jr.
• Alison F. Lawton
• Peter Harwin
• Tomas Kiselak

Industry Context

Dianthus Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on autoimmune diseases. The industry is characterized by rapid scientific advancements, long development cycles, and significant regulatory hurdles. Success hinges on robust R&D, successful clinical trials, and securing substantial funding to advance product candidates.

Top Tags

10-Q (4) · pharmaceuticals (4) · financials (4) · biotech (4) · Dianthus Therapeutics (4) · material-agreement (3) · corporate-governance (3) · SEC Filing (3) · institutional-ownership (3) · Biotechnology (2)

Key Numbers

• Net Loss: $97.905M — Increased from $56.529M in 2024, a 73.1% increase for the nine months ended September 30, 2025
• Research and Development Expenses: $85.743M — Increased from $56.692M in 2024, a 51.2% increase for the nine months ended September 30, 2025
• Proceeds from Public Offering: $272.268M — Significant capital raise during the nine months ended September 30, 2025
• Cash and Short-term Investments: $402.613M — Increased from $275.241M at December 31, 2024, as of September 30, 2025
• Total Revenues: $1.752M — Decreased from $4.909M in 2024 for the nine months ended September 30, 2025
• General and Administrative Expenses: $24.401M — Increased from $18.165M in 2024 for the nine months ended September 30, 2025
• Shares of Common Stock Outstanding: 42,876,015 — As of November 3, 2025
• SEC File Number: 001-38541 — Identifies the company's filing with the SEC.
• Fiscal Year End: 1231 — Indicates the end of the company's fiscal year for financial reporting.
• IRS Employer Identification No.: 81-0724163 — Tax identification number for the company.
• Revenue: $0 — No revenue reported for the period, typical for a pre-commercial biotech.
• Accumulated Deficit: $300.0M — As of June 30, 2025, highlighting historical losses.
• Reporting Period: Q1 2025 — Period covered by the 10-Q filing
• As of Date: March 31, 2025 — Date to which financial information pertains
• Filing Date: 20250410 — Date the DEF 14A was submitted

Forward-Looking Statements

• {"claim":"GV 2016, L.P. will continue to be a significant institutional holder in Dianthus Therapeutics.","entity":"GV 2016, L.P.","targetDate":"Next 12 months","confidence":"high"}

Related Companies

DTHX

Frequently Asked Questions